Improved AAV tropism is essential for gene therapy to reach its full potential. New capsid engineering techniques are taking on this challenge. Clinical translation of gene therapies has a history ...

Underpinning Voyager’s mission is its trademark AAV capsid-discovery platform, Tropism Redirection of AAV by Cell-type-specific Expression of RNA (TRACER). This broadly applicable, functional ...

According to Carter, the company is seeking to overcome these challenges through their TRACER™ (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) capsid discovery platform.

The Company is advancing an innovative therapeutics pipeline based on novel AAV capsid variants with unprecedented potency, specificity, and tropism. Latus was founded by technology from Professor ...

Organoids were cultured from healthy donor iPSC sources and differentiated using the human iPSC-derived Cerebral Organoid ...

Researchers prefer AAV vectors due to their broad tissue tropism, high safety profile, and adaptability in manufacturing procedures. In the present review, researchers explored AAV-vectored ...

Agreement allows Andelyn to use Stanton Lab CNS capsids to perform R&D services for clients developing gene therapies.

AAV vector evaluation in vitro for retinal gene ... A collection of tests to evaluate post-transduction cell viability, cell tropism, and transduction efficiency is an example of a viral vector ...

In addition, first-generation CRISPR systems (Cas9 and Cas12a) are too large for efficient in vivo delivery via a single adeno-associated viral (AAV) vector. Now, new preclinical research ...

Abeona’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. For more information, visit www.abeonatherapeutics.com.

The Company is advancing an innovative therapeutics pipeline based on novel AAV capsid variants with unprecedented potency, specificity, and tropism. Latus was founded by technology from Professor ...

PHILADELPHIA, February 24, 2025--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, is pleased to announce data presentations in support of ...